Siyuan Shen Selected Research

Choroidal Neovascularization

1/2018	The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.
12/2015	Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.
9/2014	Reliability of the mouse model of choroidal neovascularization induced by laser photocoagulation.
1/2014	Lack of involvement of CEP adducts in TLR activation and in angiogenesis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Siyuan Shen Research Topics

Disease

9	Neoplasms (Cancer) 09/2023 - 01/2021
4	Uterine Cervical Neoplasms (Cancer of the Cervix) 09/2023 - 07/2021
4	Choroidal Neovascularization 01/2018 - 01/2014
3	Inflammation (Inflammations) 01/2023 - 01/2021
3	Ovarian Neoplasms (Ovarian Cancer) 01/2023 - 05/2022
3	Fibrosis (Cirrhosis) 01/2023 - 12/2020
3	Macular Degeneration (Age-Related Maculopathy) 01/2018 - 01/2014
2	Cerebral Hemorrhage 05/2024 - 01/2023
2	Hypertension (High Blood Pressure) 01/2023 - 12/2020
2	Heart Failure 01/2023 - 08/2022
2	Vascular Remodeling 01/2021 - 12/2020
1	Wounds and Injuries (Trauma) 01/2023
1	Cardiomegaly (Heart Hypertrophy) 01/2023
1	Genomic Instability 01/2023
1	Hyperlipidemias (Hyperlipidemia) 01/2023
1	Reperfusion Injury 01/2023
1	Stroke (Strokes) 01/2023
1	Carcinogenesis 07/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Ulcerative Colitis 12/2021
1	Crohn Disease (Crohn's Disease) 12/2021
1	Colorectal Neoplasms (Colorectal Cancer) 12/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 12/2021
1	Autistic Disorder (Autism) 10/2021
1	Bipolar Disorder (Manic Depressive Psychosis) 10/2021
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 10/2021
1	Psychotic Disorders (Schizoaffective Disorder) 10/2021
1	Esophageal Neoplasms (Esophageal Cancer) 01/2021
1	Vascular System Injuries 12/2020
1	Vascular Diseases (Vascular Disease) 01/2017
1	Retinal Diseases 01/2017
1	Shock 10/2015
1	Necrosis 10/2015
1	Burns 09/2014
1	Corneal Neovascularization 01/2014
1	Infections 06/2006
1	Viremia 10/2005

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2005
6	Biomarkers (Surrogate Marker)IBA 01/2023 - 01/2021
3	6-methyladenineIBA 09/2023 - 10/2022
3	Angiotensin IIIBA 01/2023 - 12/2020
2	AlbuminsIBA 05/2024 - 01/2023
2	Lactic Acid (Lactate)FDA LinkGeneric 05/2024 - 01/2023
2	Long Noncoding RNAIBA 09/2023 - 01/2023
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 10/2005
2	RNA (Ribonucleic Acid)IBA 10/2022 - 01/2022
2	Toll-Like Receptor 2IBA 12/2020 - 01/2014
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018 - 12/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017 - 12/2015
1	MicroRNAs (MicroRNA)IBA 09/2023
1	Immune Checkpoint InhibitorsIBA 05/2023
1	costunolideIBA 01/2023
1	leonurineIBA 01/2023
1	Lovastatin (Mevacor)FDA LinkGeneric 01/2023
1	NF-kappa B (NF-kB)IBA 01/2023
1	Therapeutic UsesIBA 01/2023
1	Mitogen-Activated Protein KinasesIBA 01/2023
1	tabersonineIBA 08/2022
1	p38 Mitogen-Activated Protein KinasesIBA 08/2022
1	CaspasesIBA 07/2022
1	sharpinIBA 07/2022
1	Messenger RNA (mRNA)IBA 07/2022
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 05/2022
1	Drug CombinationsIBA 01/2022
1	Antipsychotic Agents (Antipsychotics)IBA 10/2021
1	Toll-Like Receptor 4IBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	acrizanibIBA 01/2018
1	Ranibizumab (Lucentis)FDA Link 01/2017
1	afliberceptIBA 01/2017
1	Peptides (Polypeptides)IBA 01/2017
1	Retinaldehyde (Retinal)IBA 01/2017
1	Dexamethasone (Maxidex)FDA LinkGeneric 10/2015
1	SteroidsIBA 10/2015
1	Anaphylatoxin C5a ReceptorIBA 09/2014
1	cobra venom factorIBA 09/2014
1	Complement System Proteins (Complement)IBA 09/2014
1	Complement Receptors (Complement Receptor)IBA 09/2014
1	Small Interfering RNA (siRNA)IBA 09/2014
1	Myeloid Differentiation Factor 88IBA 01/2014
1	env Gene ProductsIBA 06/2006
1	Neutralizing AntibodiesIBA 06/2006
1	Aligeron (AS 2)IBA 06/2006
1	VaccinesIBA 10/2005

Therapy/Procedure

8	Therapeutics 07/2022 - 12/2015
2	Lasers (Laser) 09/2014 - 01/2014
1	Drug Therapy (Chemotherapy) 01/2022
1	Duration of Therapy 10/2021
1	Immunotherapy 01/2021
1	Topical Administration 01/2018
1	Intravitreal Injections 01/2018
1	Light Coagulation 09/2014